Curis to Present at the 28th Annual Roth Conference
March 08, 2016 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., March 08, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis to Present at the Cowen and Company 36th Annual Health Care Conference
March 01, 2016 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis Reports Fourth Quarter and Year-End 2015 Financial Results
February 29, 2016 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis to Release Fourth Quarter and Year End 2015 Financial Results and Hold Conference Call on February 29, 2016
February 22, 2016 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis to Present at the 2016 RBC Capital Markets Global Healthcare Conference
February 17, 2016 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis to Present at the BIO CEO & Investor Conference
February 01, 2016 16:05 ET
|
Curis, Inc.
LEXINGTON, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting
December 06, 2015 13:15 ET
|
Curis, Inc.
CUDC-907 (HDAC and PI3K inhibitor) demonstrates objective responses, including complete responses, in patients with relapsed/ refractory DLBCL with MYC alterations
Curis expects to initiate a...
Curis to Present at the Oppenheimer 26th Annual Healthcare Conference
December 02, 2015 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis Reports Third Quarter 2015 Financial Results
November 09, 2015 07:00 ET
|
Curis, Inc.
LEXINGTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA and IRAK4 Programs at AACR-NCI-EORTC International Conference
November 08, 2015 12:30 ET
|
Curis, Inc.
LEXINGTON, Mass., Nov. 8, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...